Nuvalent 2024 Overview - ROS1+ and ALK+ NSCLC Programs

Nuvalent is a clinical-stage biotech company developing targeted therapies for ROS1+ and ALK+ non-small cell lung cancer. The company has two parallel lead programs (NVL-520 and NVL-655) in global clinical development, with a third program for HER2+ NSCLC in IND-enabling studies. Nasdaq-listed with 90+ employees and cash runway extending into 2027.